TREK Channel Activator Compounds for Potency and Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a scarcity of potent, efficacious, and selective activators for TREK-1, TREK-2, or both TREK-1 and TREK-2 channels, which are effective in treating disorders associated with TREK (TWIK Related K+ channels) dysfunction.
Innovation Solution
Development of specific compounds, such as those represented by formula (I), which act as activators for TREK-1, TREK-2, or both, to treat various disorders by modulating potassium channel activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing TREK channel activators are used, then some therapeutic benefit is achieved, but they lack sufficient potency and selectivity
Solution Approach 1:
The patent modifies molecular parameters including the core heterocyclic structure (pyridine, pyrimidine, or pyrazine rings), substituent positions (R1-R6 groups), and linker configurations to optimize both potency and selectivity. Specific parameter ranges are defined: R1-R3 are hydrogen or C1-C4 alkyl; R4 is halogen, SF5, or C1-C4 alkyl with specific substituents; R5 is aryl or heteroaryl. These controlled parameter variations within defined ranges achieve enhanced therapeutic efficacy while maintaining manageable molecular complexity.
2Adaptability or versatility
If broad-spectrum K2P channel activators are used, then multiple channel types are affected, but selectivity for TREK-1 and TREK-2 is reduced
Solution Approach 1:
The patent introduces specific local structural features at key positions to achieve selective interaction with TREK-1 and TREK-2 channels. The heterocyclic core (pyridine, pyrimidine, or pyrazine) combined with specific substituent patterns (R4 as halogen, SF5, or substituted alkyl; R5 as aryl or heteroaryl) creates localized interaction zones that distinguish TREK channels from other K2P subtypes. This local structural optimization enables selective activation without requiring broad structural complexity.
3Reliability
If highly selective TREK channel activators are developed, then therapeutic specificity is improved, but the scarcity of such compounds limits availability
Solution Approach 1:
The patent designs a universal molecular scaffold (formula I) that can selectively activate both TREK-1 and TREK-2 channels through a common structural mechanism. The heterocyclic core with specific substituent patterns serves as a universal recognition element for TREK channels, allowing a single compound design to address multiple TREK-related disorders. This multi-functional approach increases compound availability by providing a versatile template that can be optimized for different therapeutic indications while maintaining selectivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively activate TREK channels, providing therapeutic benefits for conditions like pain, ischemia, polycystic kidney disease, osteoporosis, and other TREK channel-related disorders, demonstrating improved efficacy over existing treatments.
Implementation Method 1
TREK-1, TREK-2, which belong to TREK subgroup, are thermo- and mechano-gated K+ channel that is activated by lysophospholipids and polyunsaturated fatty acids (PUFAs) including arachidonic acid
Data Source
AI summary
Disclosed is a compound of formula (I):wherein all symbols are defined in the description. Also disclosed are pharmaceutical compositions comprising the compounds, methods of making the compounds, kits comprising the compounds, and methods of using the compounds, compositions and kits for treatment of disorders associated with TREK-1, TREK-2 or both TREK-1 and TREK-2 dysfunction in a mammal.